COVID-19 vaccine challenges: What have we learned so far and what remains to be done?
•Significant global interest exists around generation of safe and effective COVID-19 vaccines.•Addressing eleven challenges (among many others) could greatly benefit COVID-19 vaccine policies.•These challenges fall under three dimensions – vaccine development, dissemination, and deployment.•Decision...
Uložené v:
| Vydané v: | Health policy (Amsterdam) Ročník 125; číslo 5; s. 553 - 567 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Ireland
Elsevier B.V
01.05.2021
Elsevier Science Ltd The Author(s). Published by Elsevier B.V |
| Predmet: | |
| ISSN: | 0168-8510, 1872-6054, 1872-6054 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | •Significant global interest exists around generation of safe and effective COVID-19 vaccines.•Addressing eleven challenges (among many others) could greatly benefit COVID-19 vaccine policies.•These challenges fall under three dimensions – vaccine development, dissemination, and deployment.•Decision-makers can anticipate and recognize these challenges, and strategize solutions at scale.•Effective vaccines can add to our existing arsenal of weapons against COVID-19.
Developing and distributing a safe and effective SARS-CoV-2 (COVID-19) vaccine has garnered immense global interest. Less than a year after COVID-19 was declared a pandemic, several vaccine candidates had received emergency use authorization across a range of countries. Despite this scientific breakthrough, the journey from vaccine discovery to global herd immunity against COVID-19 continues to present significant policy challenges that require a collaborative, global response. We offer a framework for understanding remaining and new policy challenges for successful global vaccine campaigns against COVID-19 as well as potential solutions to address them. Decision-makers must be aware of these challenges and strategize solutions that can be implemented at scale. These include challenges around maintaining R&D incentives, running clinical trials, authorizations, post-market surveillance, manufacturing and supply, global dissemination, allocation, uptake, and clinical system adaption. Alongside these challenges, financial and ethical concerns must also be addressed. |
|---|---|
| AbstractList | Developing and distributing a safe and effective SARS-CoV-2 (COVID-19) vaccine has garnered immense global interest. Less than a year after COVID-19 was declared a pandemic, several vaccine candidates had received emergency use authorization across a range of countries. Despite this scientific breakthrough, the journey from vaccine discovery to global herd immunity against COVID-19 continues to present significant policy challenges that require a collaborative, global response. We offer a framework for understanding remaining and new policy challenges for successful global vaccine campaigns against COVID-19 as well as potential solutions to address them. Decision-makers must be aware of these challenges and strategize solutions that can be implemented at scale. These include challenges around maintaining R&D incentives, running clinical trials, authorizations, post-market surveillance, manufacturing and supply, global dissemination, allocation, uptake, and clinical system adaption. Alongside these challenges, financial and ethical concerns must also be addressed.Developing and distributing a safe and effective SARS-CoV-2 (COVID-19) vaccine has garnered immense global interest. Less than a year after COVID-19 was declared a pandemic, several vaccine candidates had received emergency use authorization across a range of countries. Despite this scientific breakthrough, the journey from vaccine discovery to global herd immunity against COVID-19 continues to present significant policy challenges that require a collaborative, global response. We offer a framework for understanding remaining and new policy challenges for successful global vaccine campaigns against COVID-19 as well as potential solutions to address them. Decision-makers must be aware of these challenges and strategize solutions that can be implemented at scale. These include challenges around maintaining R&D incentives, running clinical trials, authorizations, post-market surveillance, manufacturing and supply, global dissemination, allocation, uptake, and clinical system adaption. Alongside these challenges, financial and ethical concerns must also be addressed. •Significant global interest exists around generation of safe and effective COVID-19 vaccines.•Addressing eleven challenges (among many others) could greatly benefit COVID-19 vaccine policies.•These challenges fall under three dimensions – vaccine development, dissemination, and deployment.•Decision-makers can anticipate and recognize these challenges, and strategize solutions at scale.•Effective vaccines can add to our existing arsenal of weapons against COVID-19. Developing and distributing a safe and effective SARS-CoV-2 (COVID-19) vaccine has garnered immense global interest. Less than a year after COVID-19 was declared a pandemic, several vaccine candidates had received emergency use authorization across a range of countries. Despite this scientific breakthrough, the journey from vaccine discovery to global herd immunity against COVID-19 continues to present significant policy challenges that require a collaborative, global response. We offer a framework for understanding remaining and new policy challenges for successful global vaccine campaigns against COVID-19 as well as potential solutions to address them. Decision-makers must be aware of these challenges and strategize solutions that can be implemented at scale. These include challenges around maintaining R&D incentives, running clinical trials, authorizations, post-market surveillance, manufacturing and supply, global dissemination, allocation, uptake, and clinical system adaption. Alongside these challenges, financial and ethical concerns must also be addressed. Developing and distributing a safe and effective SARS-CoV-2 (COVID-19) vaccine has garnered immense global interest. Less than a year after COVID-19 was declared a pandemic, several vaccine candidates had received emergency use authorization across a range of countries. Despite this scientific breakthrough, the journey from vaccine discovery to global herd immunity against COVID-19 continues to present significant policy challenges that require a collaborative, global response. We offer a framework for understanding remaining and new policy challenges for successful global vaccine campaigns against COVID-19 as well as potential solutions to address them. Decision-makers must be aware of these challenges and strategize solutions that can be implemented at scale. These include challenges around maintaining R&D incentives, running clinical trials, authorizations, post-market surveillance, manufacturing and supply, global dissemination, allocation, uptake, and clinical system adaption. Alongside these challenges, financial and ethical concerns must also be addressed. Highlights•Significant global interest exists around generation of safe and effective COVID-19 vaccines. •Addressing eleven challenges (among many others) could greatly benefit COVID-19 vaccine policies. •These challenges fall under three dimensions – vaccine development, dissemination, and deployment. •Decision-makers can anticipate and recognize these challenges, and strategize solutions at scale. •Effective vaccines can add to our existing arsenal of weapons against COVID-19. |
| Author | Mossialos, Elias Jit, Mark Shah, Soleil Forman, Rebecca Jeurissen, Patrick |
| Author_xml | – sequence: 1 givenname: Rebecca surname: Forman fullname: Forman, Rebecca organization: London School of Economics & Political Science, United Kingdom – sequence: 2 givenname: Soleil surname: Shah fullname: Shah, Soleil organization: Stanford University School of Medicine, United States – sequence: 3 givenname: Patrick surname: Jeurissen fullname: Jeurissen, Patrick organization: Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, the Netherlands – sequence: 4 givenname: Mark surname: Jit fullname: Jit, Mark organization: London School of Hygiene & Tropical Medicine, United Kingdom – sequence: 5 givenname: Elias surname: Mossialos fullname: Mossialos, Elias email: e.a.mossialos@lse.ac.uk organization: London School of Economics & Political Science, United Kingdom |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33820678$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUk1vEzEUtFARTQt_ASxx4bLB9mZtLxKtqvBVqVIPUDhaXu_broNjp_YmVf89XtJGEAnRkw9vZt74zRyhAx88IPSKkikllL9dTHvQbuhXwU0ZYXRKyimh5RM0oVKwgpNqdoAmGSkLWVFyiI5SWhBCRFnyZ-iwLCUjXMgJuppffj__UNAab7Qx1gM2vXYO_DWkd_hHrwfc6w3gW8AOdPTQ4hRwpyPWvsW34zzCUluf8BBwA7jNRk-fo6eddgle3L_H6OrTx2_zL8XF5efz-dlFYTidDcWsNgCm1XVDeSmrrtSi4rQG1lDRNpybVnRNS1oGUkrRUVMb0vyGMamprstjdLLVXa2bJbQG_BC1U6tolzreqaCt-nviba-uw0aJuhakYlngzb1ADDdrSINa2mTAOe0hrJNiFamZZHQ27nq9B12EdfT5exlV1WJWccIz6uWfjnZWHi6eAe-3ABNDShE6ZeygBxtGg9YpStSYsFqoXcJqTFiRUuWEM1_s8R9W_J95tmVCTmRjIapkLHgDrY1gBtUG-wiNkz0N46y3RrufcAdpdxGqElNEfR0bOBaQ0Vw-WY0Cp_8WeJSFXwNr7zY |
| CitedBy_id | crossref_primary_10_32322_jhsm_1767263 crossref_primary_10_1136_bmjopen_2021_049505 crossref_primary_10_3389_fpubh_2021_702699 crossref_primary_10_1186_s41182_023_00564_2 crossref_primary_10_1007_s10479_023_05267_9 crossref_primary_10_1080_00207543_2022_2110014 crossref_primary_10_1007_s12247_023_09708_7 crossref_primary_10_1155_2021_5807056 crossref_primary_10_1016_j_coviro_2021_11_002 crossref_primary_10_3390_vaccines10111943 crossref_primary_10_1016_j_socscimed_2023_116313 crossref_primary_10_1016_j_health_2023_100244 crossref_primary_10_1016_j_healthpol_2021_12_001 crossref_primary_10_1111_jpet_12590 crossref_primary_10_3390_vaccines11030675 crossref_primary_10_3390_vaccines9070781 crossref_primary_10_1016_j_healthpol_2023_104903 crossref_primary_10_1016_j_cam_2025_116781 crossref_primary_10_1093_inthealth_ihac007 crossref_primary_10_33590_emj_10301710 crossref_primary_10_1057_s41599_022_01392_1 crossref_primary_10_7189_jogh_12_03010 crossref_primary_10_1186_s12889_022_14448_3 crossref_primary_10_1080_10508406_2024_2381205 crossref_primary_10_1007_s11356_022_22661_1 crossref_primary_10_1016_j_hermed_2024_100879 crossref_primary_10_1371_journal_pone_0266120 crossref_primary_10_4236_jbm_2025_138023 crossref_primary_10_7759_cureus_28210 crossref_primary_10_2196_33260 crossref_primary_10_1016_j_heliyon_2024_e34691 crossref_primary_10_3390_philosophies7050106 crossref_primary_10_1186_s40545_021_00400_0 crossref_primary_10_1016_S0140_6736_22_00891_1 crossref_primary_10_1057_s41599_022_01106_7 crossref_primary_10_1007_s43681_021_00111_x crossref_primary_10_7759_cureus_39460 crossref_primary_10_1108_JHLSCM_07_2024_0093 crossref_primary_10_3390_world3040049 crossref_primary_10_1186_s12879_022_07823_3 crossref_primary_10_1017_S1744133124000094 crossref_primary_10_5334_aogh_4484 crossref_primary_10_2147_IDR_S380211 crossref_primary_10_1016_j_jiph_2021_06_013 crossref_primary_10_1016_j_lana_2022_100327 crossref_primary_10_1016_j_glmedi_2024_100150 crossref_primary_10_1002_puh2_70006 crossref_primary_10_1038_s41590_021_01091_0 crossref_primary_10_1016_j_micpath_2025_107724 crossref_primary_10_1080_21645515_2025_2451487 crossref_primary_10_3390_nano11051328 crossref_primary_10_3390_ijerph19053063 crossref_primary_10_26633_RPSP_2024_50 crossref_primary_10_1186_s40359_024_02048_2 crossref_primary_10_1016_j_heliyon_2022_e10728 crossref_primary_10_1136_bmjopen_2022_069294 crossref_primary_10_3389_fpubh_2022_1084017 crossref_primary_10_3390_vaccines12080885 crossref_primary_10_3389_fpubh_2021_747787 crossref_primary_10_3390_vaccines10010115 crossref_primary_10_7759_cureus_23951 crossref_primary_10_1186_s12929_021_00784_w crossref_primary_10_2174_0113894501337502241015121015 crossref_primary_10_1111_wrr_12975 crossref_primary_10_3390_systems12050167 crossref_primary_10_1016_j_jddst_2022_103762 crossref_primary_10_69547_TSFJB_020104 crossref_primary_10_1016_j_omega_2023_103001 crossref_primary_10_1080_13814788_2024_2409240 crossref_primary_10_1016_j_vaccine_2023_12_051 crossref_primary_10_1088_1361_6498_acdd7e crossref_primary_10_3389_fpubh_2025_1611028 crossref_primary_10_1016_j_ejor_2025_01_011 crossref_primary_10_1186_s12929_022_00852_9 crossref_primary_10_1016_j_micpath_2023_105994 crossref_primary_10_1038_s41598_022_13675_3 crossref_primary_10_1002_VIW_20200078 crossref_primary_10_1002_ijgo_15465 crossref_primary_10_1080_21645515_2022_2154100 crossref_primary_10_1080_00330124_2023_2215851 crossref_primary_10_1007_s44282_023_00013_9 crossref_primary_10_1016_j_ijdrr_2022_103056 crossref_primary_10_4102_hsag_v28i0_2265 crossref_primary_10_1016_j_ijnurstu_2023_104569 crossref_primary_10_1371_journal_pone_0281990 crossref_primary_10_3390_su15043121 crossref_primary_10_3390_vaccines11050974 crossref_primary_10_4102_phcfm_v16i1_4208 crossref_primary_10_1017_pls_2023_2 crossref_primary_10_1016_j_omega_2022_102783 crossref_primary_10_1016_j_ijid_2021_11_024 crossref_primary_10_3390_pharmaceutics15051349 crossref_primary_10_1016_j_healthpol_2022_05_016 crossref_primary_10_1007_s13337_022_00755_1 crossref_primary_10_1016_j_cnur_2022_10_001 crossref_primary_10_1080_14760584_2022_1999811 crossref_primary_10_3390_molecules26133868 crossref_primary_10_1016_j_heliyon_2021_e07816 crossref_primary_10_3390_vaccines10020214 crossref_primary_10_1002_cbin_11653 crossref_primary_10_3390_ijerph20064796 crossref_primary_10_1016_j_socscimed_2021_114695 crossref_primary_10_1016_j_healthpol_2022_03_008 crossref_primary_10_1016_S0140_6736_21_01995_4 crossref_primary_10_3917_sim_222_0059 crossref_primary_10_1080_21645515_2021_2007708 crossref_primary_10_1371_journal_pdig_0000150 crossref_primary_10_1007_s10479_022_04753_w crossref_primary_10_1002_ptr_7531 crossref_primary_10_3390_vaccines10040623 crossref_primary_10_1590_0102_311x00200221 crossref_primary_10_3390_vaccines9121451 crossref_primary_10_3390_jpm11121243 crossref_primary_10_1371_journal_pone_0279195 crossref_primary_10_1155_2023_3626862 crossref_primary_10_1186_s12967_022_03767_z crossref_primary_10_1155_sci5_6025826 crossref_primary_10_1089_vim_2022_0136 crossref_primary_10_1080_09720510_2021_1966955 crossref_primary_10_3389_fpubh_2021_695807 crossref_primary_10_3390_ijms251910530 crossref_primary_10_3389_fnut_2022_1033779 crossref_primary_10_2147_RMHP_S493435 crossref_primary_10_1038_s41598_022_06306_4 crossref_primary_10_1111_phn_13143 crossref_primary_10_1016_j_tre_2024_103613 crossref_primary_10_1186_s12982_025_00597_4 crossref_primary_10_1186_s41479_021_00092_9 crossref_primary_10_1371_journal_pone_0309230 crossref_primary_10_2196_33909 crossref_primary_10_3389_fnut_2022_992733 crossref_primary_10_1007_s40121_023_00859_1 crossref_primary_10_1186_s12982_024_00364_x crossref_primary_10_1016_j_imj_2023_08_005 crossref_primary_10_3390_ijerph20042902 crossref_primary_10_3390_life13091886 crossref_primary_10_2196_41404 crossref_primary_10_1080_21645515_2022_2079346 crossref_primary_10_54537_tusebdergisi_983736 crossref_primary_10_1038_s41541_023_00674_2 crossref_primary_10_3390_ijerph19169973 crossref_primary_10_1016_j_glt_2023_10_003 crossref_primary_10_3390_pharmaceutics13111895 crossref_primary_10_1016_j_healthpol_2022_07_005 crossref_primary_10_2147_RMHP_S309707 crossref_primary_10_1016_j_hlpt_2022_100699 crossref_primary_10_1016_j_ijpharm_2025_125662 crossref_primary_10_1093_cid_ciab381 crossref_primary_10_1136_bmjgh_2024_018007 crossref_primary_10_3390_su132212867 crossref_primary_10_1016_j_clinsp_2022_100109 crossref_primary_10_1108_JHLSCM_10_2021_0106 crossref_primary_10_1038_s41598_022_18392_5 crossref_primary_10_3389_fpubh_2022_814981 crossref_primary_10_1186_s12889_023_17241_y crossref_primary_10_1186_s12889_023_15903_5 crossref_primary_10_3390_vaccines10101689 crossref_primary_10_1016_j_energy_2021_121315 crossref_primary_10_3389_fpubh_2022_1002910 crossref_primary_10_7189_jogh_12_03033 crossref_primary_10_3390_vaccines9121474 crossref_primary_10_1007_s10238_023_01254_3 crossref_primary_10_1001_jamanetworkopen_2022_26892 crossref_primary_10_1039_D3BM00305A crossref_primary_10_1080_21645515_2021_1995283 crossref_primary_10_2147_JMDH_S347669 crossref_primary_10_1016_j_scitotenv_2022_153469 crossref_primary_10_1002_rmv_2475 crossref_primary_10_1016_j_healthpol_2022_05_005 crossref_primary_10_1126_sciimmunol_abo6294 crossref_primary_10_3390_vaccines10071116 crossref_primary_10_1080_13527266_2023_2191618 crossref_primary_10_1002_nav_22181 crossref_primary_10_1007_s41542_023_00153_z crossref_primary_10_1177_00953997231167557 crossref_primary_10_1186_s12889_023_16584_w crossref_primary_10_1177_00027642221138279 crossref_primary_10_1007_s40747_023_00972_1 crossref_primary_10_1038_s41598_024_77331_8 crossref_primary_10_3390_plants11182436 crossref_primary_10_1016_j_jddst_2023_104567 |
| Cites_doi | 10.1177/1529100618760521 10.1038/s41541-020-00249-5 10.1038/nrd2035 10.1186/1744-8603-9-58 10.1038/d41586-021-00727-3 10.1093/infdis/jiaa152 10.1136/bmj.n513 10.1007/s10198-020-01208-6 10.1056/NEJMp2020926 10.1136/bmj.m4845 10.1056/NEJMp2026393 10.1016/j.vaccine.2020.07.068 10.1038/d41586-020-02944-8 10.1016/S0140-6736(20)30763-7 10.1016/S2213-2600(21)00075-8 10.1126/science.abg0889 10.1016/S0140-6736(21)00501-8 10.1016/j.healthpol.2020.05.008 10.1002/hast.1113 10.1016/S0140-6736(21)00502-X 10.1136/bmj.m4058 10.3892/ijmm.2020.4596 10.1016/j.vaccine.2015.04.043 10.1016/j.socscimed.2016.01.005 10.1056/NEJMoa2007764 10.1136/bmj.m3205 10.1016/S0140-6736(21)00306-8 |
| ContentType | Journal Article |
| Copyright | 2021 The Author(s) Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved. Copyright Elsevier Science Ltd. May 2021 2021 The Author(s) 2021 |
| Copyright_xml | – notice: 2021 The Author(s) – notice: Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved. – notice: Copyright Elsevier Science Ltd. May 2021 – notice: 2021 The Author(s) 2021 |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QJ 7TQ 8BJ DHY DON FQK JBE 7X8 5PM |
| DOI | 10.1016/j.healthpol.2021.03.013 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Applied Social Sciences Index & Abstracts (ASSIA) PAIS Index International Bibliography of the Social Sciences (IBSS) PAIS International PAIS International (Ovid) International Bibliography of the Social Sciences International Bibliography of the Social Sciences MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) International Bibliography of the Social Sciences (IBSS) Applied Social Sciences Index and Abstracts (ASSIA) PAIS International MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic International Bibliography of the Social Sciences (IBSS) MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health |
| EISSN | 1872-6054 |
| EndPage | 567 |
| ExternalDocumentID | PMC7997052 33820678 10_1016_j_healthpol_2021_03_013 S0168851021000853 1_s2_0_S0168851021000853 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M ..I .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29I 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABIVO ABJNI ABMAC ABMZM ABOCM ABXDB ACDAQ ACGFS ACHQT ACIEU ACIUM ACLOT ACRLP ACVFH ADBBV ADCNI ADEZE ADMHG AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEH HMK HMO HVGLF HZ~ IHE J1W KOM M29 M3W M41 MO0 MS~ N9A O-L O9- OAUVE OHT OZT P-8 P-9 P2P PC. PQQKQ Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K TN5 UHS WUQ Z5R ZGI ~G- ~HD AACTN AFCTW AFKWA AJOXV AMFUW RIG 6I. AAFTH AAIAV ABLVK ABYKQ AJBFU LCYCR 9DU AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QJ 7TQ 8BJ DHY DON FQK JBE 7X8 5PM |
| ID | FETCH-LOGICAL-c614t-49ceecda9b16385f3a75619e2b17db66cd7fbd0d2e8887f1c9c0b5f3a728a1a93 |
| ISICitedReferencesCount | 172 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000647678700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0168-8510 1872-6054 |
| IngestDate | Tue Sep 30 15:10:45 EDT 2025 Sun Sep 28 08:02:27 EDT 2025 Sat Nov 08 20:12:09 EST 2025 Thu Apr 03 07:08:36 EDT 2025 Sat Nov 29 07:27:28 EST 2025 Tue Nov 18 21:48:58 EST 2025 Fri Feb 23 02:45:09 EST 2024 Tue Feb 25 19:54:20 EST 2025 Tue Oct 14 19:27:37 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c614t-49ceecda9b16385f3a75619e2b17db66cd7fbd0d2e8887f1c9c0b5f3a728a1a93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7997052 |
| PMID | 33820678 |
| PQID | 2559745606 |
| PQPubID | 105626 |
| PageCount | 15 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7997052 proquest_miscellaneous_2509282149 proquest_journals_2559745606 pubmed_primary_33820678 crossref_citationtrail_10_1016_j_healthpol_2021_03_013 crossref_primary_10_1016_j_healthpol_2021_03_013 elsevier_sciencedirect_doi_10_1016_j_healthpol_2021_03_013 elsevier_clinicalkeyesjournals_1_s2_0_S0168851021000853 elsevier_clinicalkey_doi_10_1016_j_healthpol_2021_03_013 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-05-01 |
| PublicationDateYYYYMMDD | 2021-05-01 |
| PublicationDate_xml | – month: 05 year: 2021 text: 2021-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Ireland |
| PublicationPlace_xml | – name: Ireland – name: Amsterdam |
| PublicationTitle | Health policy (Amsterdam) |
| PublicationTitleAlternate | Health Policy |
| PublicationYear | 2021 |
| Publisher | Elsevier B.V Elsevier Science Ltd The Author(s). Published by Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier Science Ltd – name: The Author(s). Published by Elsevier B.V |
| References | Neumann-Böhme, Varghese, Sabat, Barros, Brouwer, van Exel (bib0077) 2020; 21 Kelland (bib0011) 2021 Byanyima (bib0042) 2021 (accessed 9 March 2021). Beaubien (bib0054) 2021 Beigel, Tomashek, Dodd, Mehta, Zingman, Kalil (bib0110) 2020 (bib0021) 2020 (bib0061) 2021 Yamey, Schäferhoff, Hatchett, Pate, Zhao, McDade (bib0007) 2020; 395 Hart (bib0066) 2021 Hanif, Ali, Patel, Khunti (bib0089) 2020; 371 Mahase (bib0031) 2020; 370 Brogan, Mossialos (bib0008) 2016; 151 Hart (bib0040) 2021 Soutik (bib0033) 2020 Calina, Docea, Petrakis, Egorov, Ishmukhametov, Gabibov (bib0108) 2020; 46 Cohen, Kupferschmidt (bib0052) 2021 (accessed 8 Feb 2021). Brogan, Mossialos (bib0009) 2013; 9 Huang P. COVID-19 Vaccine Ethics: Is It Ever OK To Cut The Line? 2021. Gallagher L. Call for volunteers for world's first coronavirus human challenge study. Imp Coll London 2021. Schwartz (bib0036) 2020; 383 (accessed 1 Mar 2021). (accessed 13 March 2021). Naujokaitytė, Zubașcu (bib0024) 2020; 2020 . (accessed 2 Mar 2021). Soy (bib0045) 2021 Castillo J.C., Ahuja A., Athey S., Baker A., Budish E., Chipty T., et al. Market design to accelerate COVID-19 vaccine supply. Science (80–) 2021:eabg0889. https://doi.org/10.1126/science.abg0889. Vaccine Centre (bib0020) Brogan, Mossialos (bib0010) 2006; 5 Rowland, McGinley (bib0058) 2021 Grady (bib0094) 2020 (bib0027) 2020 World Health Organization. COVAX Announces new agreement, plans for first deliveries. 2021. Eskola, Duclos, Schuster, MacDonald, Liang, Chaudhuri (bib0092) 2015; 33 (bib0104) 2021 (bib0069) 2020 Public Health (bib0070) Carrieri, Madio, Principe (bib0081) 2019; 28 Brewer, Chapman, Rothman, Leask, Kempe (bib0095) 2017; 18 Wouters, Shadlen, Salcher-Konrad, Pollard, Larson, Teerawattananon (bib0080) 2021 (bib0023) 2020 Byrne J. COVID-19 vaccine development: setback for Sanofi and GSK candidate, University of Queensland and CSL abandon trial. BioPharma 2020. Williams, Burgers (bib0047) 2021 Bateman-House (bib0096) 2020 Doshi P. Covid-19 vaccine trial protocols released. BMJ 202AD;371:m4058. https://doi.org/10.1136/bmj.m4058. Sun, Stanley-Becker (bib0071) 2020 Razai, Osama, McKechnie, Majeed (bib0086) 2021; 372 Benjamin (bib0088) 2021 Taylor (bib0032) (bib0019) 2018; 319 World Health Organization. First COVID-19 COVAX vaccine doses administered in Africa. 2021. Forman, Anderson, Jit, Mossialos (bib0005) 2020; 38 McNeil D.G. Covid-19: how Much Herd Immunity is Enough? New York Times 2021. F.D.A. Coronavirus (COVID-19) Update: FDA Issues Policies to Guide Medical Product Developers Addressing Virus Variants. FDA 2021. Abboud, Dombey, Borrelli, Chazan (bib0030) 2021 (bib0091) 2014 (bib0035) 2021; 2021 Simpson, Chakrabarti, Robinson, Chirgwin, Lumpkin (bib0025) 2020; 5 Milne, Caulfield, Tepper (bib0097) 2020 (accessed 28 Feb 2021). Ratzan, Sommariva, Rauh (bib0085) 2020; 30 Subbarao (bib0074) 2020; 586 Kirk, Sheehy, Levett (bib0043) 2021 Bunch (bib0087) 2021 Nunez, Salzman (bib0064) 2020 Newey, Kelly-Linden (bib0056) 2020 Megget (bib0078) 2020; 369 Nawrat (bib0105) 2021 (bib0028) 2020 Cold supply for hot demand. Gavi Vaccine Alliance. 2020. Hall, Chazan, Mallet, Dombey (bib0055) 2021 (bib0109) 2020 Prendecki, Clarke, Brown, Cox, Gleeson, Guckian (bib0102) 2021 Manisty, Otter, Treibel, McKnight, Altmann, Brooks (bib0103) 2021 Beckett (bib0084) 2021 (bib0106) 2021 Duke Global Health Innovation Center. Launch and Scale Speedometer: Covid-19. 2021. (accessed 23 Sep 2020). Silverman R, Ramakrishnan G, Towse A, et al. The Race for a COVID-19 Vaccine: An Overview of Current Proposals and Our Contribution in Bringing in the Missing Middle. 2020. (accessed 23 September 2020). Key (bib0049) 2021 Wang, Schmidt, Weisblum, Muecksch, Finkin, Schaefer-Babajew (bib0002) 2021 Mello, Silverman, Omer (bib0079) 2020; 383 Mukumbang (bib0076) 2020; 5 (accessed 9 Mar 2021). Guarascio (bib0029) 2020 (bib0012) 2020 Robbins, Mueller (bib0018) 2020 Isaac, Kang (bib0083) 2020 (bib0026) 2020; 588 (bib0072) 2021 Ahuja (bib0004) 2021 Medicines and Healthcare Products Regulatory Agency. Oxford University/AstraZeneca COVID-19 vaccine approved. 2020. Forman, Atun, McKee, Mossialos (bib0059) 2020 Bosely (bib0053) 2020 (bib0099) 2020 EPHA. Getting it right: Recommendations for a European BARDA. 2020.https://epha.org/getting-it-right-recommendations-for-a-european-barda. (accessed 17 December 2020). Eyal, Lipsitch, Smith (bib0017) 2020; 221 (bib0003) 2021 (bib0013) 2021 (accessed 22 Sep 2020). International Chamber of Commerce. Study shows vaccine nationalism could cost rich countries US$4.5 trillion. Int Chamb Commer 2021. Schmidt (bib0075) 2020; 50 Gavi Board calls for global access to COVID-19 vaccines. Gavi Vaccine Alliance 2020. Buckley (bib0068) 2021 Koukakis (bib0060) 2021 (bib0101) 2021 tables and charts - COVID-19 Vaccine Advance Market Commitments (accessed 8 Feb 2021). Boffey (bib0044) 2021 (bib0100) 2021 ICMRA. ICMRA: COVID-19. ICMRA 2021. Chodick, Tene, Patalon, Gazit, Ben Tov, Cohen (bib0038) 2021 (accessed 8 February 2021). Nandy R, O’Brien K, Linstrand A. Immunization services in the context of Covid 19. 2020. Cohen (bib0001) 2020 Mossialos (bib0006) 2020 bib0067 Farguharson C. Overcoming vaccine hesitancy in our diverse communities. 2021. (bib0082) 2020 Roberts (bib0111) 2020 Irwin (bib112) 2021 Godfrey H. Covid-19 vaccine refusers may face different life insurance policies. City AM 2020. Wouters (10.1016/j.healthpol.2021.03.013_bib0080) 2021 Bunch (10.1016/j.healthpol.2021.03.013_bib0087) 2021 Guarascio (10.1016/j.healthpol.2021.03.013_bib0029) 2020 Forman (10.1016/j.healthpol.2021.03.013_bib0059) 2020 Buckley (10.1016/j.healthpol.2021.03.013_bib0068) 2021 (10.1016/j.healthpol.2021.03.013_bib0027) 2020 Brogan (10.1016/j.healthpol.2021.03.013_bib0009) 2013; 9 Vaccine Centre (10.1016/j.healthpol.2021.03.013_bib0020) Brogan (10.1016/j.healthpol.2021.03.013_bib0010) 2006; 5 Brewer (10.1016/j.healthpol.2021.03.013_bib0095) 2017; 18 10.1016/j.healthpol.2021.03.013_bib0062 Eskola (10.1016/j.healthpol.2021.03.013_bib0092) 2015; 33 10.1016/j.healthpol.2021.03.013_bib0063 Benjamin (10.1016/j.healthpol.2021.03.013_bib0088) 2021 Ratzan (10.1016/j.healthpol.2021.03.013_bib0085) 2020; 30 Mahase (10.1016/j.healthpol.2021.03.013_bib0031) 2020; 370 10.1016/j.healthpol.2021.03.013_bib0067 (10.1016/j.healthpol.2021.03.013_bib0021) 2020 10.1016/j.healthpol.2021.03.013_bib0107 Newey (10.1016/j.healthpol.2021.03.013_bib0056) 2020 Megget (10.1016/j.healthpol.2021.03.013_bib0078) 2020; 369 Taylor (10.1016/j.healthpol.2021.03.013_bib0032) 10.1016/j.healthpol.2021.03.013_bib0073 Nawrat (10.1016/j.healthpol.2021.03.013_bib0105) 2021 (10.1016/j.healthpol.2021.03.013_bib0082) 2020 (10.1016/j.healthpol.2021.03.013_bib0026) 2020; 588 Williams (10.1016/j.healthpol.2021.03.013_bib0047) 2021 Hanif (10.1016/j.healthpol.2021.03.013_bib0089) 2020; 371 Milne (10.1016/j.healthpol.2021.03.013_bib0097) 2020 Rowland (10.1016/j.healthpol.2021.03.013_bib0058) 2021 Mello (10.1016/j.healthpol.2021.03.013_bib0079) 2020; 383 Abboud (10.1016/j.healthpol.2021.03.013_bib0030) 2021 Hall (10.1016/j.healthpol.2021.03.013_bib0055) 2021 Kelland (10.1016/j.healthpol.2021.03.013_bib0011) 2021 10.1016/j.healthpol.2021.03.013_bib0041 Boffey (10.1016/j.healthpol.2021.03.013_bib0044) 2021 10.1016/j.healthpol.2021.03.013_bib0046 (10.1016/j.healthpol.2021.03.013_bib0101) 2021 10.1016/j.healthpol.2021.03.013_bib0048 Grady (10.1016/j.healthpol.2021.03.013_bib0094) 2020 Key (10.1016/j.healthpol.2021.03.013_bib0049) 2021 Ahuja (10.1016/j.healthpol.2021.03.013_bib0004) 2021 (10.1016/j.healthpol.2021.03.013_bib0061) 2021 (10.1016/j.healthpol.2021.03.013_bib0003) 2021 Chodick (10.1016/j.healthpol.2021.03.013_bib0038) 2021 Soy (10.1016/j.healthpol.2021.03.013_bib0045) 2021 Soutik (10.1016/j.healthpol.2021.03.013_bib0033) 2020 10.1016/j.healthpol.2021.03.013_bib0051 10.1016/j.healthpol.2021.03.013_bib0050 Forman (10.1016/j.healthpol.2021.03.013_bib0005) 2020; 38 Manisty (10.1016/j.healthpol.2021.03.013_bib0103) 2021 10.1016/j.healthpol.2021.03.013_bib0057 (10.1016/j.healthpol.2021.03.013_bib0072) 2021 (10.1016/j.healthpol.2021.03.013_bib0109) 2020 (10.1016/j.healthpol.2021.03.013_bib0019) 2018; 319 Brogan (10.1016/j.healthpol.2021.03.013_bib0008) 2016; 151 Prendecki (10.1016/j.healthpol.2021.03.013_bib0102) 2021 Hart (10.1016/j.healthpol.2021.03.013_bib0066) 2021 Robbins (10.1016/j.healthpol.2021.03.013_bib0018) 2020 10.1016/j.healthpol.2021.03.013_bib0022 (10.1016/j.healthpol.2021.03.013_bib0106) 2021 Wang (10.1016/j.healthpol.2021.03.013_bib0002) 2021 Hart (10.1016/j.healthpol.2021.03.013_bib0040) 2021 Irwin (10.1016/j.healthpol.2021.03.013_bib112) 2021 Neumann-Böhme (10.1016/j.healthpol.2021.03.013_bib0077) 2020; 21 Mossialos (10.1016/j.healthpol.2021.03.013_bib0006) 2020 Naujokaitytė (10.1016/j.healthpol.2021.03.013_bib0024) 2020; 2020 Beaubien (10.1016/j.healthpol.2021.03.013_bib0054) 2021 Subbarao (10.1016/j.healthpol.2021.03.013_bib0074) 2020; 586 (10.1016/j.healthpol.2021.03.013_bib0013) 2021 Mukumbang (10.1016/j.healthpol.2021.03.013_bib0076) 2020; 5 (10.1016/j.healthpol.2021.03.013_bib0035) 2021; 2021 Roberts (10.1016/j.healthpol.2021.03.013_bib0111) 2020 (10.1016/j.healthpol.2021.03.013_bib0028) 2020 Carrieri (10.1016/j.healthpol.2021.03.013_bib0081) 2019; 28 (10.1016/j.healthpol.2021.03.013_bib0100) 2021 Public Health (10.1016/j.healthpol.2021.03.013_bib0070) 10.1016/j.healthpol.2021.03.013_bib0034 10.1016/j.healthpol.2021.03.013_bib0037 10.1016/j.healthpol.2021.03.013_bib0039 (10.1016/j.healthpol.2021.03.013_bib0091) 2014 Beckett (10.1016/j.healthpol.2021.03.013_bib0084) 2021 Koukakis (10.1016/j.healthpol.2021.03.013_bib0060) 2021 (10.1016/j.healthpol.2021.03.013_bib0012) 2020 (10.1016/j.healthpol.2021.03.013_bib0104) 2021 Beigel (10.1016/j.healthpol.2021.03.013_bib0110) 2020 Byanyima (10.1016/j.healthpol.2021.03.013_bib0042) 2021 (10.1016/j.healthpol.2021.03.013_bib0069) 2020 (10.1016/j.healthpol.2021.03.013_bib0099) 2020 Cohen (10.1016/j.healthpol.2021.03.013_bib0001) 2020 Bateman-House (10.1016/j.healthpol.2021.03.013_bib0096) 2020 Schwartz (10.1016/j.healthpol.2021.03.013_bib0036) 2020; 383 Razai (10.1016/j.healthpol.2021.03.013_bib0086) 2021; 372 Calina (10.1016/j.healthpol.2021.03.013_bib0108) 2020; 46 Eyal (10.1016/j.healthpol.2021.03.013_bib0017) 2020; 221 (10.1016/j.healthpol.2021.03.013_bib0023) 2020 Yamey (10.1016/j.healthpol.2021.03.013_bib0007) 2020; 395 Bosely (10.1016/j.healthpol.2021.03.013_bib0053) 2020 Cohen (10.1016/j.healthpol.2021.03.013_bib0052) 2021 Sun (10.1016/j.healthpol.2021.03.013_bib0071) 2020 Nunez (10.1016/j.healthpol.2021.03.013_bib0064) 2020 10.1016/j.healthpol.2021.03.013_bib0090 10.1016/j.healthpol.2021.03.013_bib0093 Simpson (10.1016/j.healthpol.2021.03.013_bib0025) 2020; 5 Kirk (10.1016/j.healthpol.2021.03.013_bib0043) 2021 10.1016/j.healthpol.2021.03.013_bib0098 Isaac (10.1016/j.healthpol.2021.03.013_bib0083) 2020 10.1016/j.healthpol.2021.03.013_bib0015 10.1016/j.healthpol.2021.03.013_bib0014 Schmidt (10.1016/j.healthpol.2021.03.013_bib0075) 2020; 50 10.1016/j.healthpol.2021.03.013_bib0016 |
| References_xml | – ident: bib0070 – volume: 151 start-page: 167 year: 2016 end-page: 172 ident: bib0008 article-title: Systems, not pills: the options market for antibiotics seeks to rejuvenate the antibiotic pipeline publication-title: Soc Sci Med – year: 2020 ident: bib0059 article-title: 12 Lessons learned from the management of the coronavirus pandemic publication-title: Health Policy (New York) – volume: 371 start-page: m4845 year: 2020 ident: bib0089 article-title: Cultural competence in covid-19 vaccine rollout publication-title: BMJ – volume: 588 year: 2020 ident: bib0026 article-title: COVID vaccines: the world’s medical regulators need access to open data publication-title: Nature – year: 2021 ident: bib0045 article-title: Africa's long wait for the Covid-19 vaccine – reference: World Health Organization. COVAX Announces new agreement, plans for first deliveries. 2021. – reference: F.D.A. Coronavirus (COVID-19) Update: FDA Issues Policies to Guide Medical Product Developers Addressing Virus Variants. FDA 2021. – reference: World Health Organization. First COVID-19 COVAX vaccine doses administered in Africa. 2021. – year: 2020 ident: bib0083 article-title: While twitter confronts trump, Zuckerberg keeps facebook out of it – reference: (accessed 17 December 2020). – year: 2021 ident: bib0013 article-title: Promoting our european way of life publication-title: Eur Parliam – reference: Castillo J.C., Ahuja A., Athey S., Baker A., Budish E., Chipty T., et al. Market design to accelerate COVID-19 vaccine supply. Science (80–) 2021:eabg0889. https://doi.org/10.1126/science.abg0889. – year: 2021 ident: bib0101 article-title: ‘No jab, no job’ policies may be legal for new staff publication-title: BBC News – volume: 369 year: 2020 ident: bib0078 article-title: Even covid-19 can't kill the anti-vaccination movement publication-title: BMJ – year: 2020 ident: bib0097 article-title: Seven ways to talk to anti-vaxxers (that might actually change their minds) – year: 2021 ident: bib0061 article-title: The WTO has a new chief. Is it time for new trade rules too? – reference: (accessed 8 February 2021). – year: 2020 ident: bib0001 article-title: Breakthrough of the year 2020: shots of hope – year: 2020 ident: bib0094 article-title: Pfizer's covid vaccine and allergies: how concerned should you be? – reference: Byrne J. COVID-19 vaccine development: setback for Sanofi and GSK candidate, University of Queensland and CSL abandon trial. BioPharma 2020. – volume: 2020 year: 2020 ident: bib0024 article-title: EU to create new biomedical research agency modelled on BARDA publication-title: Sci Bus – reference: Gavi Board calls for global access to COVID-19 vaccines. Gavi Vaccine Alliance 2020. – reference: Medicines and Healthcare Products Regulatory Agency. Oxford University/AstraZeneca COVID-19 vaccine approved. 2020. – reference: International Chamber of Commerce. Study shows vaccine nationalism could cost rich countries US$4.5 trillion. Int Chamb Commer 2021. – reference: (accessed 8 Feb 2021). – year: 2021 ident: bib0106 article-title: World health organization. global influenza surveillance and response system (GISRS) – year: 2020 ident: bib0109 article-title: Oxford COVID-19 study: face masks and coverings work – act now – reference: (accessed 13 March 2021). – volume: 221 start-page: 1752 year: 2020 end-page: 1756 ident: bib0017 article-title: Human challenge studies to accelerate coronavirus vaccine licensure publication-title: J Infect Dis – volume: 383 start-page: 1703 year: 2020 end-page: 1705 ident: bib0036 article-title: Evaluating and Deploying Covid-19 Vaccines — the importance of transparency, scientific integrity, and public trust publication-title: N Engl J Med – year: 2020 ident: bib0027 article-title: European union officially approves pfizer vaccine for rollout – reference: Godfrey H. Covid-19 vaccine refusers may face different life insurance policies. City AM 2020. – year: 2020 ident: bib0069 article-title: SARS-CoV-2 vaccine development & implementation; scenarios, options – year: 2020 ident: bib0021 article-title: An international randomised trial of candidate vaccines against COVID-19 – volume: 28 start-page: 1377 year: 2019 end-page: 1382 ident: bib0081 article-title: Vaccine hesitancy and (fake) news: quasi-experimental evidence from Italy publication-title: Heal Econ (United Kingdom) – year: 2021 ident: bib0044 article-title: Germany voices concern over Italy's block of vaccine export to Australia – reference: (accessed 28 Feb 2021). – reference: Doshi P. Covid-19 vaccine trial protocols released. BMJ 202AD;371:m4058. https://doi.org/10.1136/bmj.m4058. – year: 2021 ident: bib0003 article-title: Merck discontinues development of SARS-CoV-2/COVID-19 vaccine candidates – year: 2020 ident: bib0071 article-title: Health-care workers and nursing home residents should be the first to get coronavirus vaccines publication-title: CDC advisory group says – year: 2020 ident: bib0056 article-title: Very high’ risk WHO-led vaccine scheme could fail, internal documents reveal publication-title: Telegr – reference: Farguharson C. Overcoming vaccine hesitancy in our diverse communities. 2021. – year: 2021 ident: bib0105 article-title: Genomics and Covid-19: uK’s real-time surveillance tracks viral mutations publication-title: Pharm Technol – reference: ICMRA. ICMRA: COVID-19. ICMRA 2021. – volume: 18 start-page: 149 year: 2017 end-page: 207 ident: bib0095 article-title: Increasing Vaccination: putting psychological science into action publication-title: Psychol Sci Public Interes – reference: Huang P. COVID-19 Vaccine Ethics: Is It Ever OK To Cut The Line? 2021. – year: 2020 ident: bib0023 article-title: Clinical trial regulation european medicines agency publication-title: Emerg Med Agency 2020 – volume: 5 year: 2020 ident: bib0025 article-title: Navigating facilitated regulatory pathways during a disease X pandemic publication-title: NPJ Vaccines – reference: EPHA. Getting it right: Recommendations for a European BARDA. 2020.https://epha.org/getting-it-right-recommendations-for-a-european-barda. – volume: 586 start-page: 475 year: 2020 ident: bib0074 article-title: COVID-19 vaccines: time to talk about the uncertainties publication-title: Nature – volume: 2021 year: 2021 ident: bib0035 article-title: Adapting COVID-19 vaccines to SARS-CoV-2 variants: guidance for vaccine manufacturers publication-title: EMA – volume: 46 start-page: 3 year: 2020 end-page: 16 ident: bib0108 article-title: Towards effective COVID‑19 vaccines: updates, perspectives and challenges (Review) publication-title: Int J Mol Med – year: 2020 ident: bib0033 article-title: What was the rush to approve India’s homegrown vaccine? – year: 2021 ident: bib0038 article-title: The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence – volume: 21 start-page: 977 year: 2020 end-page: 982 ident: bib0077 article-title: Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19 publication-title: Eur J Heal Econ – year: 2021 ident: bib0103 article-title: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals publication-title: Lancet – year: 2021 ident: bib0002 article-title: mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants publication-title: BioRxiv – reference: Silverman R, Ramakrishnan G, Towse A, et al. The Race for a COVID-19 Vaccine: An Overview of Current Proposals and Our Contribution in Bringing in the Missing Middle. 2020. – year: 2021 ident: bib0102 article-title: Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine publication-title: Lancet – reference: (accessed 9 March 2021). – volume: 38 start-page: 6075 year: 2020 end-page: 6077 ident: bib0005 article-title: Ensuring access and affordability through COVID-19 vaccine research and development investments: a proposal for the options market for vaccines publication-title: Vaccine – volume: 395 start-page: 1405 year: 2020 end-page: 1406 ident: bib0007 article-title: Ensuring global access to COVID-19 vaccines publication-title: Lancet – reference: (accessed 9 Mar 2021). – reference: Nandy R, O’Brien K, Linstrand A. Immunization services in the context of Covid 19. 2020. – year: 2021 ident: bib0004 article-title: A universal Covid vaccine may be our best means of escape – reference: McNeil D.G. Covid-19: how Much Herd Immunity is Enough? New York Times 2021. – year: 2021 ident: bib0066 article-title: Three key challenges for the covid vaccine supply chain publication-title: Supply Manag – ident: bib0032 – volume: 5 start-page: 641 year: 2006 end-page: 647 ident: bib0010 article-title: Applying the concepts of financial options to stimulate vaccine development publication-title: Nat Rev Drug Discov – reference: (accessed 1 Mar 2021). – year: 2020 ident: bib0099 article-title: Vaccination will be required to fly, says Qantas chief publication-title: BBC News – year: 2020 ident: bib0029 article-title: EU criticises ‘hasty’ UK approval of COVID-19 vaccine – year: 2020 ident: bib0096 article-title: Who Will Be the Face of Covid-19 Vaccination? A Few Helpful Suggestions publication-title: Barrons – year: 2021 ident: bib0043 article-title: Canada and UK among countries with most vaccine doses ordered per person – volume: 9 start-page: 58 year: 2013 ident: bib0009 article-title: Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model publication-title: Global Health – year: 2020 ident: bib0082 article-title: Facebook and twitter restrict trump accounts over ‘harmful’ virus claim – start-page: 1 year: 2021 end-page: 12 ident: bib0087 article-title: A tale of two crises: addressing Covid-19 vaccine hesitancy as promoting racial justice publication-title: HEC Forum – year: 2020 ident: bib0053 article-title: Belgian minister tweets EU's Covid vaccine price list to anger of manufacturers – reference: Gallagher L. Call for volunteers for world's first coronavirus human challenge study. Imp Coll London 2021. – reference: tables and charts - COVID-19 Vaccine Advance Market Commitments (accessed 8 Feb 2021). – year: 2021 ident: bib0058 article-title: Merck to help make Johnson & Johnson coronavirus vaccine – year: 2020 ident: bib0012 article-title: Speech by President von der Leyen at the EU Health publication-title: Summit – year: 2020 ident: bib0111 article-title: Coronavirus: dexamethasone proves first life-saving drug – reference: (accessed 23 Sep 2020). – year: 2021 ident: bib112 article-title: What it will take to vaccinate the world against COVID-19 publication-title: Nature – volume: 50 start-page: 46 year: 2020 end-page: 49 ident: bib0075 article-title: Vaccine rationing and the urgency of social justice in the Covid-19 response publication-title: Hastings Cent Rep – year: 2021 ident: bib0100 article-title: EU urged to adopt ‘vaccine passports publication-title: BBC News – year: 2021 ident: bib0104 article-title: Covid: france says just one jab needed for previously infected publication-title: BBC News – year: 2021 ident: bib0054 article-title: Price check: nations pay wildly different prices for vaccines – reference: Duke Global Health Innovation Center. Launch and Scale Speedometer: Covid-19. 2021. – year: 2021 ident: bib0011 article-title: Coalition eyes 100-day target for new vaccines against disease epidemics – year: 2021 ident: bib0072 article-title: Access and allocation: how will there be fair and equitable allocation of limited supplies? publication-title: World Heal Organ – volume: 383 start-page: 1296 year: 2020 end-page: 1299 ident: bib0079 article-title: Ensuring Uptake of Vaccines against SARS-CoV-2 publication-title: N Engl J Med – volume: 372 start-page: n513 year: 2021 ident: bib0086 article-title: Covid-19 vaccine hesitancy among ethnic minority groups publication-title: BMJ – year: 2021 ident: bib0047 article-title: SARS-CoV-2 evolution and vaccines: cause for concern? publication-title: Lancet Respir Med – year: 2014 ident: bib0091 article-title: Strategies for addressing vaccine hesitancy – year: 2021 ident: bib0042 article-title: A global vaccine apartheid is unfolding publication-title: People's lives must come before profit – volume: 5 start-page: 4085 year: 2020 ident: bib0076 article-title: Are asylum seekers, refugees and foreign migrants considered in the COVID-19 vaccine discourse? publication-title: BMJ Glob Heal – year: 2021 ident: bib0088 article-title: Why are we vaccine hesitant in a pandemic? publication-title: Br Med Assoc – year: 2021 ident: bib0055 article-title: Shortage of coronavirus shots heaps pressure on European leaders – reference: (accessed 22 Sep 2020). – ident: bib0067 – year: 2021 ident: bib0052 article-title: Countries now scrambling for COVID-19 vaccines may soon have surpluses to donate publication-title: Sci Mag – volume: 319 year: 2018 ident: bib0019 article-title: Clinical trials have far too little racial and ethnic diversity publication-title: Sci Am – reference: Cold supply for hot demand. Gavi Vaccine Alliance. 2020. – year: 2021 ident: bib0040 article-title: EU vaccine woes grow with Pfizer supply ‘30% lower than expected publication-title: Supply Manag – ident: bib0020 – reference: (accessed 23 September 2020). – year: 2020 ident: bib0064 article-title: Strained supply chain for glass vials could delay coronavirus vaccine publication-title: ABC News – year: 2021 ident: bib0080 article-title: Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment publication-title: Lancet – year: 2020 ident: bib0028 article-title: Fauci apologises for saying UK ‘rushed’ vaccine – volume: 33 start-page: 4215 year: 2015 end-page: 4217 ident: bib0092 article-title: How to deal with vaccine hesitancy? publication-title: Vaccine – year: 2021 ident: bib0030 publication-title: Europe's AstraZeneca stockpile mounts as citizens snub jab – year: 2021 ident: bib0049 article-title: Outcomes: covax amc 2021 – reference: . – year: 2020 ident: bib0006 article-title: Paying innovators is the way out of lockdown – volume: 30 year: 2020 ident: bib0085 article-title: Enhancing global health communication during a crisis: lessons from the COVID-19 pandemic publication-title: Public Heal Res Pract – year: 2021 ident: bib0068 article-title: Vaccine shipments present a security challenge worthy of a James Bond film – reference: (accessed 2 Mar 2021). – year: 2020 ident: bib0018 article-title: After admitting mistake publication-title: AstraZeneca faces difficult questions about its vaccine – year: 2021 ident: bib0084 article-title: Misinformation ‘superspreaders’: covid vaccine falsehoods still thriving on facebook and instagram – volume: 370 start-page: m3205 year: 2020 ident: bib0031 article-title: Covid-19: russia approves vaccine without large scale testing or published results publication-title: BMJ – year: 2020 ident: bib0110 article-title: Remdesivir for the Treatment of Covid-19 - Preliminary Report publication-title: N Engl J Med – reference: (accessed 17 December 2020). – year: 2021 ident: bib0060 article-title: Countries worldwide look to acquire the intellectual property rights of covid-19 vaccine makers – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0044 – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0083 – ident: 10.1016/j.healthpol.2021.03.013_bib0037 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0061 – ident: 10.1016/j.healthpol.2021.03.013_bib0014 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0106 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0002 article-title: mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants publication-title: BioRxiv – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0006 – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0069 – ident: 10.1016/j.healthpol.2021.03.013_bib0098 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0054 – ident: 10.1016/j.healthpol.2021.03.013_bib0020 – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0027 – ident: 10.1016/j.healthpol.2021.03.013_bib0046 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0066 article-title: Three key challenges for the covid vaccine supply chain publication-title: Supply Manag – volume: 2021 year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0035 article-title: Adapting COVID-19 vaccines to SARS-CoV-2 variants: guidance for vaccine manufacturers publication-title: EMA – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0038 – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0001 – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0033 – volume: 18 start-page: 149 year: 2017 ident: 10.1016/j.healthpol.2021.03.013_bib0095 article-title: Increasing Vaccination: putting psychological science into action publication-title: Psychol Sci Public Interes doi: 10.1177/1529100618760521 – volume: 5 year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0025 article-title: Navigating facilitated regulatory pathways during a disease X pandemic publication-title: NPJ Vaccines doi: 10.1038/s41541-020-00249-5 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0072 article-title: Access and allocation: how will there be fair and equitable allocation of limited supplies? publication-title: World Heal Organ – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0013 article-title: Promoting our european way of life publication-title: Eur Parliam – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0030 publication-title: Europe's AstraZeneca stockpile mounts as citizens snub jab – ident: 10.1016/j.healthpol.2021.03.013_bib0070 – volume: 5 start-page: 641 year: 2006 ident: 10.1016/j.healthpol.2021.03.013_bib0010 article-title: Applying the concepts of financial options to stimulate vaccine development publication-title: Nat Rev Drug Discov doi: 10.1038/nrd2035 – volume: 588 year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0026 article-title: COVID vaccines: the world’s medical regulators need access to open data publication-title: Nature – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0064 article-title: Strained supply chain for glass vials could delay coronavirus vaccine publication-title: ABC News – ident: 10.1016/j.healthpol.2021.03.013_bib0016 – ident: 10.1016/j.healthpol.2021.03.013_bib0041 – volume: 9 start-page: 58 year: 2013 ident: 10.1016/j.healthpol.2021.03.013_bib0009 article-title: Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model publication-title: Global Health doi: 10.1186/1744-8603-9-58 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib112 article-title: What it will take to vaccinate the world against COVID-19 publication-title: Nature doi: 10.1038/d41586-021-00727-3 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0101 article-title: ‘No jab, no job’ policies may be legal for new staff publication-title: BBC News – volume: 221 start-page: 1752 year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0017 article-title: Human challenge studies to accelerate coronavirus vaccine licensure publication-title: J Infect Dis doi: 10.1093/infdis/jiaa152 – volume: 372 start-page: n513 year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0086 article-title: Covid-19 vaccine hesitancy among ethnic minority groups publication-title: BMJ doi: 10.1136/bmj.n513 – year: 2014 ident: 10.1016/j.healthpol.2021.03.013_bib0091 – volume: 319 year: 2018 ident: 10.1016/j.healthpol.2021.03.013_bib0019 article-title: Clinical trials have far too little racial and ethnic diversity publication-title: Sci Am – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0040 article-title: EU vaccine woes grow with Pfizer supply ‘30% lower than expected publication-title: Supply Manag – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0043 – volume: 21 start-page: 977 year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0077 article-title: Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19 publication-title: Eur J Heal Econ doi: 10.1007/s10198-020-01208-6 – volume: 383 start-page: 1296 year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0079 article-title: Ensuring Uptake of Vaccines against SARS-CoV-2 publication-title: N Engl J Med doi: 10.1056/NEJMp2020926 – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0082 – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0053 – ident: 10.1016/j.healthpol.2021.03.013_bib0063 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0068 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0052 article-title: Countries now scrambling for COVID-19 vaccines may soon have surpluses to donate publication-title: Sci Mag – volume: 371 start-page: m4845 year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0089 article-title: Cultural competence in covid-19 vaccine rollout publication-title: BMJ doi: 10.1136/bmj.m4845 – volume: 383 start-page: 1703 year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0036 article-title: Evaluating and Deploying Covid-19 Vaccines — the importance of transparency, scientific integrity, and public trust publication-title: N Engl J Med doi: 10.1056/NEJMp2026393 – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0056 article-title: Very high’ risk WHO-led vaccine scheme could fail, internal documents reveal publication-title: Telegr – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0111 – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0071 article-title: Health-care workers and nursing home residents should be the first to get coronavirus vaccines – volume: 38 start-page: 6075 year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0005 article-title: Ensuring access and affordability through COVID-19 vaccine research and development investments: a proposal for the options market for vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2020.07.068 – volume: 586 start-page: 475 year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0074 article-title: COVID-19 vaccines: time to talk about the uncertainties publication-title: Nature doi: 10.1038/d41586-020-02944-8 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0100 article-title: EU urged to adopt ‘vaccine passports publication-title: BBC News – volume: 30 year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0085 article-title: Enhancing global health communication during a crisis: lessons from the COVID-19 pandemic publication-title: Public Heal Res Pract – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0058 – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0018 article-title: After admitting mistake – ident: 10.1016/j.healthpol.2021.03.013_bib0062 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0049 – volume: 395 start-page: 1405 year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0007 article-title: Ensuring global access to COVID-19 vaccines publication-title: Lancet doi: 10.1016/S0140-6736(20)30763-7 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0045 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0047 article-title: SARS-CoV-2 evolution and vaccines: cause for concern? publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(21)00075-8 – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0109 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0003 – ident: 10.1016/j.healthpol.2021.03.013_bib0032 – ident: 10.1016/j.healthpol.2021.03.013_bib0107 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0084 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0011 – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0029 – ident: 10.1016/j.healthpol.2021.03.013_bib0057 doi: 10.1126/science.abg0889 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0103 article-title: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals publication-title: Lancet doi: 10.1016/S0140-6736(21)00501-8 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0088 article-title: Why are we vaccine hesitant in a pandemic? publication-title: Br Med Assoc – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0059 article-title: 12 Lessons learned from the management of the coronavirus pandemic publication-title: Health Policy (New York) doi: 10.1016/j.healthpol.2020.05.008 – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0023 article-title: Clinical trial regulation european medicines agency publication-title: Emerg Med Agency 2020 – ident: 10.1016/j.healthpol.2021.03.013_bib0015 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0104 article-title: Covid: france says just one jab needed for previously infected publication-title: BBC News – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0097 – ident: 10.1016/j.healthpol.2021.03.013_bib0050 – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0096 article-title: Who Will Be the Face of Covid-19 Vaccination? A Few Helpful Suggestions publication-title: Barrons – ident: 10.1016/j.healthpol.2021.03.013_bib0039 – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0094 – volume: 50 start-page: 46 year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0075 article-title: Vaccine rationing and the urgency of social justice in the Covid-19 response publication-title: Hastings Cent Rep doi: 10.1002/hast.1113 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0105 article-title: Genomics and Covid-19: uK’s real-time surveillance tracks viral mutations publication-title: Pharm Technol – ident: 10.1016/j.healthpol.2021.03.013_bib0093 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0102 article-title: Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine publication-title: Lancet doi: 10.1016/S0140-6736(21)00502-X – volume: 5 start-page: 4085 year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0076 article-title: Are asylum seekers, refugees and foreign migrants considered in the COVID-19 vaccine discourse? publication-title: BMJ Glob Heal – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0012 article-title: Speech by President von der Leyen at the EU Health publication-title: Summit – ident: 10.1016/j.healthpol.2021.03.013_bib0022 doi: 10.1136/bmj.m4058 – volume: 46 start-page: 3 year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0108 article-title: Towards effective COVID‑19 vaccines: updates, perspectives and challenges (Review) publication-title: Int J Mol Med doi: 10.3892/ijmm.2020.4596 – ident: 10.1016/j.healthpol.2021.03.013_bib0051 – ident: 10.1016/j.healthpol.2021.03.013_bib0048 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0060 – volume: 28 start-page: 1377 year: 2019 ident: 10.1016/j.healthpol.2021.03.013_bib0081 article-title: Vaccine hesitancy and (fake) news: quasi-experimental evidence from Italy publication-title: Heal Econ (United Kingdom) – volume: 2020 year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0024 article-title: EU to create new biomedical research agency modelled on BARDA publication-title: Sci Bus – ident: 10.1016/j.healthpol.2021.03.013_bib0067 – start-page: 1 year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0087 article-title: A tale of two crises: addressing Covid-19 vaccine hesitancy as promoting racial justice publication-title: HEC Forum – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0004 – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0028 – ident: 10.1016/j.healthpol.2021.03.013_bib0034 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0055 – ident: 10.1016/j.healthpol.2021.03.013_bib0090 – volume: 33 start-page: 4215 year: 2015 ident: 10.1016/j.healthpol.2021.03.013_bib0092 article-title: How to deal with vaccine hesitancy? publication-title: Vaccine doi: 10.1016/j.vaccine.2015.04.043 – volume: 151 start-page: 167 year: 2016 ident: 10.1016/j.healthpol.2021.03.013_bib0008 article-title: Systems, not pills: the options market for antibiotics seeks to rejuvenate the antibiotic pipeline publication-title: Soc Sci Med doi: 10.1016/j.socscimed.2016.01.005 – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0110 article-title: Remdesivir for the Treatment of Covid-19 - Preliminary Report publication-title: N Engl J Med doi: 10.1056/NEJMoa2007764 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0042 article-title: A global vaccine apartheid is unfolding – ident: 10.1016/j.healthpol.2021.03.013_bib0073 – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0099 article-title: Vaccination will be required to fly, says Qantas chief publication-title: BBC News – year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0021 – volume: 369 year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0078 article-title: Even covid-19 can't kill the anti-vaccination movement publication-title: BMJ – volume: 370 start-page: m3205 year: 2020 ident: 10.1016/j.healthpol.2021.03.013_bib0031 article-title: Covid-19: russia approves vaccine without large scale testing or published results publication-title: BMJ doi: 10.1136/bmj.m3205 – year: 2021 ident: 10.1016/j.healthpol.2021.03.013_bib0080 article-title: Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment publication-title: Lancet doi: 10.1016/S0140-6736(21)00306-8 |
| SSID | ssj0007336 |
| Score | 2.6605182 |
| SecondaryResourceType | review_article |
| Snippet | •Significant global interest exists around generation of safe and effective COVID-19 vaccines.•Addressing eleven challenges (among many others) could greatly... Highlights•Significant global interest exists around generation of safe and effective COVID-19 vaccines. •Addressing eleven challenges (among many others)... Developing and distributing a safe and effective SARS-CoV-2 (COVID-19) vaccine has garnered immense global interest. Less than a year after COVID-19 was... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 553 |
| SubjectTerms | Authorization Campaigns Candidates Challenges Clinical research Clinical trials Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - administration & dosage Decision makers Dissemination Ethics Humans Immunity Immunization Internal Medicine Pandemics R&D Research & development SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Surveillance Uptake Vaccines |
| Title | COVID-19 vaccine challenges: What have we learned so far and what remains to be done? |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0168851021000853 https://www.clinicalkey.es/playcontent/1-s2.0-S0168851021000853 https://dx.doi.org/10.1016/j.healthpol.2021.03.013 https://www.ncbi.nlm.nih.gov/pubmed/33820678 https://www.proquest.com/docview/2559745606 https://www.proquest.com/docview/2509282149 https://pubmed.ncbi.nlm.nih.gov/PMC7997052 |
| Volume | 125 |
| WOSCitedRecordID | wos000647678700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1872-6054 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007336 issn: 0168-8510 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9owELdou4dJ07TPjq2rPGl7QqnyQbDdlwm1VCuq6KTBxJvlJI6gooEBhf4R-6N3FzuhtExlD3uJIseOE98v57vLfRDyOWAq0bC1Oixh2qmHkedEvI4GeJGEaVpPY98Um2CdDu_3xfdK5XcRC7MYsSzjt7di8l9JDW1AbAyd_QdylzeFBjgHosMRyA7HrQh_cvnz_NTxRG2hYvxrjrG9pl5K7v2GubprA6w5tNSmZoRGy3ktVcabconXp_paoe8MCKaRriXjTN9zALTRS5M8qzBKqc1rzLiQILxK04I1rloKlracgcpNOT_GI73y72hrzGZozUGmbkAZQ9QerocVWSOF761cAi1f5cx3QHMytgO9oa1gxiYM2qIuvMNaQ5NU-AHLN9aHqyMTNwrvfYQPkGeuNVGu60m2O5fyrHdxIbutfhc-rskvByuQ4Z_6L8GpQcMO2fNZKIBH7jXPW_12ubNj6khU4IsHX_MX3Dj_36Sdh9rMfafcO1JO9wV5btUT2jSwekkqOntFnhnbLjVEf016BcSohRhdQeyYIsAoAowuNbUAo7MxBYBRABhFgFELMDof00hTBNjXN6R31uqefHNseQ4nBplu7tQFCFhxokSEMn2YBoqBMC60H3ksiRqNOGFplLiJrznsZKkXi9iN8m4-V54SwVuym8H93xGqkoh5qqGY4kFdqFSlqWDoTsB4osM4rZJGsYwytrnrsYTKSBZOileyXH-J6y_dQML6V4lbDpyY9C2PD-EFnWQRnQz7qQS8PT6UbRqqZ5Y9zKQnZ7500aWywUHXQYMLKj0w8rgcaUVfI9JuN-1BASdZzmRMBaDPNKrkU3kZ9g78IagyPb7BPq7wue_VRZXsG_SVqxQEeWUHDu-0hsuyA-alX7-SDQd5fnomBHND__0W834gT1fs4oDszqc3-iN5Ei_mw9n0kOywPj-0X-EfORMCDw |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=COVID-19+vaccine+challenges%3A+What+have+we+learned+so+far+and+what+remains+to+be+done%3F&rft.jtitle=Health+policy+%28Amsterdam%29&rft.au=man%2C+Rebecca&rft.au=Shah%2C+Soleil&rft.au=Jeurissen%2C+Patrick&rft.au=Jit%2C+Mark&rft.date=2021-05-01&rft.issn=1872-6054&rft.eissn=1872-6054&rft.volume=125&rft.issue=5&rft.spage=553&rft_id=info:doi/10.1016%2Fj.healthpol.2021.03.013&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0168-8510&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0168-8510&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0168-8510&client=summon |